US5179017A
(en)
|
1980-02-25 |
1993-01-12 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US4634665A
(en)
|
1980-02-25 |
1987-01-06 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US4475196A
(en)
|
1981-03-06 |
1984-10-02 |
Zor Clair G |
Instrument for locating faults in aircraft passenger reading light and attendant call control system
|
US4447233A
(en)
|
1981-04-10 |
1984-05-08 |
Parker-Hannifin Corporation |
Medication infusion pump
|
US4439196A
(en)
|
1982-03-18 |
1984-03-27 |
Merck & Co., Inc. |
Osmotic drug delivery system
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
US4447224A
(en)
|
1982-09-20 |
1984-05-08 |
Infusaid Corporation |
Variable flow implantable infusion apparatus
|
US4487603A
(en)
|
1982-11-26 |
1984-12-11 |
Cordis Corporation |
Implantable microinfusion pump system
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4486194A
(en)
|
1983-06-08 |
1984-12-04 |
James Ferrara |
Therapeutic device for administering medicaments through the skin
|
EP0154316B1
(en)
|
1984-03-06 |
1989-09-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified lymphokine and production thereof
|
US4596556A
(en)
|
1985-03-25 |
1986-06-24 |
Bioject, Inc. |
Hypodermic injection apparatus
|
US5374548A
(en)
|
1986-05-02 |
1994-12-20 |
Genentech, Inc. |
Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
|
MX9203291A
(en)
|
1985-06-26 |
1992-08-01 |
Liposome Co Inc |
LIPOSOMAS COUPLING METHOD.
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
US4881175A
(en)
|
1986-09-02 |
1989-11-14 |
Genex Corporation |
Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
US5013653A
(en)
|
1987-03-20 |
1991-05-07 |
Creative Biomolecules, Inc. |
Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
|
US5091513A
(en)
|
1987-05-21 |
1992-02-25 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
DE3856559T2
(en)
|
1987-05-21 |
2004-04-29 |
Micromet Ag |
Multifunctional proteins with predetermined objectives
|
US5132405A
(en)
|
1987-05-21 |
1992-07-21 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
US5258498A
(en)
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
US4941880A
(en)
|
1987-06-19 |
1990-07-17 |
Bioject, Inc. |
Pre-filled ampule and non-invasive hypodermic injection device assembly
|
US4790824A
(en)
|
1987-06-19 |
1988-12-13 |
Bioject, Inc. |
Non-invasive hypodermic injection device
|
GB8717430D0
(en)
|
1987-07-23 |
1987-08-26 |
Celltech Ltd |
Recombinant dna product
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
GB8809129D0
(en)
|
1988-04-18 |
1988-05-18 |
Celltech Ltd |
Recombinant dna methods vectors and host cells
|
US5476996A
(en)
|
1988-06-14 |
1995-12-19 |
Lidak Pharmaceuticals |
Human immune system in non-human animal
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
DE68925966T2
(en)
|
1988-12-22 |
1996-08-29 |
Kirin Amgen Inc |
CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5108921A
(en)
|
1989-04-03 |
1992-04-28 |
Purdue Research Foundation |
Method for enhanced transmembrane transport of exogenous molecules
|
US5312335A
(en)
|
1989-11-09 |
1994-05-17 |
Bioject Inc. |
Needleless hypodermic injection device
|
US5064413A
(en)
|
1989-11-09 |
1991-11-12 |
Bioject, Inc. |
Needleless hypodermic injection device
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
EP1690935A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
ES2246502T3
(en)
|
1990-08-29 |
2006-02-16 |
Genpharm International, Inc. |
TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5874299A
(en)
|
1990-08-29 |
1999-02-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5789650A
(en)
|
1990-08-29 |
1998-08-04 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
ATE275198T1
(en)
|
1991-12-02 |
2004-09-15 |
Medical Res Council |
PRODUCTION OF ANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES.
|
JPH07503132A
(en)
|
1991-12-17 |
1995-04-06 |
ジェンファーム インターナショナル,インコーポレイティド |
Transgenic non-human animals capable of producing xenoantibodies
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
CA2118508A1
(en)
|
1992-04-24 |
1993-11-11 |
Elizabeth S. Ward |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
US5383851A
(en)
|
1992-07-24 |
1995-01-24 |
Bioject Inc. |
Needleless hypodermic injection device
|
AU6819494A
(en)
|
1993-04-26 |
1994-11-21 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
WO1995006407A1
(en)
|
1993-08-30 |
1995-03-09 |
The Regents Of The University Of California |
Novel component of amyloid in alzheimer's disease and methods for use of same
|
AU1444095A
(en)
|
1993-12-27 |
1995-07-17 |
Baxter International Inc. |
Water soluble non-immunogenic polyamide cross-linking agents
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5767135A
(en)
|
1995-12-29 |
1998-06-16 |
Fernandez-Pol; Jose Alberto |
Antiviral agent
|
DE69731289D1
(en)
|
1996-03-18 |
2004-11-25 |
Univ Texas |
IMMUNGLOBULIN-LIKE DOMAIN WITH INCREASED HALF-VALUE TIMES
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
DE69833755T2
(en)
|
1997-05-21 |
2006-12-28 |
Biovation Ltd. |
METHOD FOR PRODUCING NON-IMMUNOGENOUS PROTEINS
|
US7001720B1
(en)
|
1997-06-25 |
2006-02-21 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Cloning of a gene mutation for parkinson's disease
|
US6913745B1
(en)
|
1997-12-02 |
2005-07-05 |
Neuralab Limited |
Passive immunization of Alzheimer's disease
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
DK1071700T3
(en)
|
1998-04-20 |
2010-06-07 |
Glycart Biotechnology Ag |
Glycosylation modification of antibodies to enhance antibody-dependent cellular cytotoxicity
|
US20040014142A1
(en)
|
1998-07-03 |
2004-01-22 |
Innogenetics N.V. |
Differential diagnosis of neurodegeneration
|
US20020137139A1
(en)
|
1999-01-12 |
2002-09-26 |
Byatt John C |
Nucleic acid and other molecules associated with lactation and muscle and fat deposition
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
EP2364997A3
(en)
|
1999-01-15 |
2012-07-04 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
ES2420835T3
(en)
|
1999-04-09 |
2013-08-27 |
Kyowa Hakko Kirin Co., Ltd. |
Procedure to control the activity of immunofunctional molecules
|
US20040146521A1
(en)
|
1999-06-01 |
2004-07-29 |
Schenk Dale B. |
Prevention and treatment of synucleinopathic disease
|
EP1074563A1
(en)
|
1999-08-02 |
2001-02-07 |
F. Hoffmann-La Roche Ag |
Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
|
US6633559B1
(en)
|
1999-08-11 |
2003-10-14 |
Ericsson Inc. |
Apparatus and methods for extended base station range using staggered uplink frame structures
|
EP1212422B1
(en)
|
1999-08-24 |
2007-02-21 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
AU4018201A
(en)
|
1999-09-23 |
2001-04-24 |
Incyte Genomics, Inc. |
Molecules for diagnostics and therapeutics
|
US20040048249A1
(en)
|
2000-01-21 |
2004-03-11 |
Tang Y. Tom |
Novel nucleic acids and secreted polypeptides
|
AU4314801A
(en)
|
2000-02-11 |
2001-08-20 |
Lexigen Pharm Corp |
Enhancing the circulating half-life of antibody-based fusion proteins
|
CA2415179A1
(en)
|
2000-07-07 |
2002-01-17 |
Panacea Pharmaceuticals, Inc. |
Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
|
CA2414772C
(en)
|
2000-07-07 |
2011-06-28 |
Jan Naslund |
Prevention and treatment of alzheimer's disease
|
US6725230B2
(en)
|
2000-07-18 |
2004-04-20 |
Aegis Analytical Corporation |
System, method and computer program for assembling process data of multi-database origins using a hierarchical display
|
IL155977A0
(en)
|
2000-11-30 |
2003-12-23 |
Medarex Inc |
Transgenic transchromosomal rodents for making human antibodies
|
WO2002050121A1
(en)
|
2000-12-13 |
2002-06-27 |
Taisho Pharmaceutical Co.,Ltd. |
Novel antibody
|
AU2002246734A1
(en)
|
2000-12-27 |
2002-08-12 |
University Of Texas Health Science Center Houston |
Prion isomers, methods of making, methods of using, and compositions and products comprising prion isomers
|
WO2002065136A2
(en)
|
2001-02-15 |
2002-08-22 |
University Of Chicago |
Yeast screens for agents affecting protein folding
|
CA2448981C
(en)
|
2001-05-31 |
2014-03-18 |
Arete Associates |
Misfolded protein sensor method
|
EP1434778A4
(en)
|
2001-05-31 |
2005-07-13 |
Medarex Inc |
Cytotoxins, prodrugs, linkers and stabilizers useful therefor
|
WO2003000714A2
(en)
|
2001-06-22 |
2003-01-03 |
Panacea Pharmaceuticals, Inc. |
Compositions and methods for preventing protein aggregation in neurodegenerative diseases
|
CA2453344A1
(en)
|
2001-07-21 |
2003-01-21 |
Nuvelo, Inc. |
Novel nucleic acids and secreted polypeptides
|
US7247426B2
(en)
|
2001-08-02 |
2007-07-24 |
Agilent Technologies, Inc. |
Classifying cancers
|
AU2002313737A1
(en)
|
2001-08-13 |
2003-04-01 |
University Of Kentucky Research Foundation |
Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment
|
US20060241074A1
(en)
|
2001-08-14 |
2006-10-26 |
The General Hospital Corporation |
Methods for treatment of pain
|
US20040101876A1
(en)
|
2002-05-31 |
2004-05-27 |
Liat Mintz |
Methods and systems for annotating biomolecular sequences
|
JP2005532253A
(en)
|
2001-10-25 |
2005-10-27 |
ジェネンテック・インコーポレーテッド |
Glycoprotein composition
|
EP1451217A4
(en)
|
2001-11-20 |
2005-10-12 |
Atgen Co Ltd |
Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
|
EP1572894B1
(en)
|
2001-11-21 |
2016-04-13 |
New York University |
Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha synuclein, or polyglutamine repeats for induction of an immune response thereto
|
US20040248156A1
(en)
|
2001-12-03 |
2004-12-09 |
Tianhua Hu |
Methods and materials relating to novel C1q domain-containing polypeptides and polynucleotides
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US7425620B2
(en)
|
2002-08-14 |
2008-09-16 |
Scott Koenig |
FcγRIIB-specific antibodies and methods of use thereof
|
AU2003270643A1
(en)
|
2002-09-12 |
2004-04-30 |
The Regents Of The University Of California |
Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
|
CN1705491B
(en)
|
2002-09-27 |
2013-05-29 |
赞科股份有限公司 |
Optimized Fc variants and methods for their generation
|
AU2003286467B2
(en)
|
2002-10-15 |
2009-10-01 |
Abbvie Biotherapeutics Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US20080014194A1
(en)
|
2003-10-31 |
2008-01-17 |
Elan Pharmaceuticals, Inc. |
Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
|
US8506959B2
(en)
|
2002-11-01 |
2013-08-13 |
Neotope Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
US9034337B2
(en)
|
2003-10-31 |
2015-05-19 |
Prothena Biosciences Limited |
Treatment and delay of outset of synucleinopathic and amyloidogenic disease
|
TW200509968A
(en)
|
2002-11-01 |
2005-03-16 |
Elan Pharm Inc |
Prevention and treatment of synucleinopathic disease
|
AU2003290743A1
(en)
|
2002-11-12 |
2004-06-03 |
Genentech, Inc. |
Compositions and methods for the treatment of rheumatoid arthritis
|
AU2003283205A1
(en)
|
2002-11-26 |
2004-06-18 |
Danmarks Fodevare- Og Veterinaerforskning |
Dendrimer conjugates for selective of protein aggregates
|
EP2368578A1
(en)
|
2003-01-09 |
2011-09-28 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
US7749695B2
(en)
|
2003-03-03 |
2010-07-06 |
Alexander Abbas |
PRO polypeptides for diagnosis of systemic lupus erythematosis
|
HUE035044T2
(en)
|
2003-05-19 |
2018-05-02 |
Prothena Biosciences Ltd |
Truncated fragments of alpha-synuclein in Lewy body disease
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
WO2005047860A2
(en)
|
2003-11-08 |
2005-05-26 |
Elan Pharmaceuticals, Inc. |
Antibodies to alpha-synuclein
|
UA86605C2
(en)
|
2004-01-12 |
2009-05-12 |
Аплайд Молекьюлер Иволюшн, Инк. |
Antibody comprising a variant fc region
|
EP2053062A1
(en)
|
2004-03-24 |
2009-04-29 |
Xencor, Inc. |
Immunoglobin variants outside the Fc region
|
US20050240352A1
(en)
|
2004-04-23 |
2005-10-27 |
Invitrogen Corporation |
Online procurement of biologically related products/services using interactive context searching of biological information
|
RU2402548C2
(en)
|
2004-05-19 |
2010-10-27 |
Медарекс, Инк. |
Chemical linkers and conjugates thereof
|
BRPI0510909A2
(en)
|
2004-05-19 |
2008-12-16 |
Medarex Inc |
cytotoxic drug-binder binding compound, pharmaceutical formulation, method for killing a cell and method for retarding or stopping tumor growth
|
DK1776384T3
(en)
|
2004-08-04 |
2013-09-02 |
Mentrik Biotech Llc |
VARIANT Fc REGIONS
|
MX2007001679A
(en)
|
2004-08-09 |
2007-05-23 |
Elan Pharm Inc |
Prevention and treatment of synucleinopathic and amyloidogenic disease.
|
US20060057671A1
(en)
|
2004-09-10 |
2006-03-16 |
Orser Cindy S |
Immobilized probes and methods of detecting conformationally altered prion proteins
|
AU2005300688B2
(en)
|
2004-11-03 |
2012-02-02 |
Almac Diagnostics Limited |
Transcriptome microarray technology and methods of using the same
|
JP2008527005A
(en)
|
2005-01-14 |
2008-07-24 |
ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニア |
Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
|
US7714016B2
(en)
|
2005-04-08 |
2010-05-11 |
Medarex, Inc. |
Cytotoxic compounds and conjugates with cleavable substrates
|
MX2007014537A
(en)
|
2005-05-18 |
2008-02-12 |
Wyeth Corp |
Leukemia disease genes and uses thereof.
|
WO2007011907A2
(en)
|
2005-07-19 |
2007-01-25 |
University Of Rochester |
Alpha-synuclein antibodies and methods related thereto
|
WO2007021255A1
(en)
|
2005-08-09 |
2007-02-22 |
Elan Pharmaceuticals, Inc. |
Antibodies to alpha-synuclein
|
EA016577B1
(en)
|
2005-09-26 |
2012-06-29 |
Медарекс, Инк. |
Antibody-drug conjugates and use thereof
|
DK1940789T3
(en)
|
2005-10-26 |
2012-03-19 |
Medarex Inc |
Methods and Compounds for the Preparation of CC-1065 Analogs
|
CA2627190A1
(en)
|
2005-11-10 |
2007-05-24 |
Medarex, Inc. |
Duocarmycin derivatives as novel cytotoxic compounds and conjugates
|
WO2007090126A2
(en)
|
2006-01-30 |
2007-08-09 |
Invitrogen Corporation |
Compositions and methods for detecting and quantifying toxic substances in disease states
|
WO2007089862A2
(en)
|
2006-01-31 |
2007-08-09 |
Elan Pharmaceuticals, Inc. |
Alpha-synuclein kinase
|
GB0602992D0
(en)
|
2006-02-15 |
2006-03-29 |
Morvus Technology Ltd |
Methods, genes and proteins
|
US8378072B2
(en)
|
2006-04-13 |
2013-02-19 |
Declion Pharmaceuticals, Inc. |
Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
|
WO2007140011A2
(en)
|
2006-05-26 |
2007-12-06 |
The Government Of The United States Of America |
Erythroid progenitor cells and methods for producing parvovirus b19 therein
|
US20110201686A1
(en)
|
2006-06-23 |
2011-08-18 |
Yousef Al-Abed |
Inhibitors of ASS and Synuclein Aggregation
|
JP2009544306A
(en)
|
2006-07-25 |
2009-12-17 |
ドイチェス クレブスフォルシュングスツェントルム |
Common gene expression signature for dilated cardiomyopathy
|
WO2008034016A2
(en)
|
2006-09-15 |
2008-03-20 |
Foldrx Pharmaceuticals, Inc. |
Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins
|
CL2007003622A1
(en)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method.
|
TWI412367B
(en)
|
2006-12-28 |
2013-10-21 |
Medarex Llc |
Chemical linkers and cleavable substrates and conjugates thereof
|
CA2678514A1
(en)
|
2007-02-21 |
2008-08-28 |
Medarex, Inc. |
Chemical linkers with single amino acids and conjugates thereof
|
EP3067066B1
(en)
|
2007-02-23 |
2019-03-27 |
Prothena Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
US8147833B2
(en)
|
2007-02-23 |
2012-04-03 |
Neotope Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
CA2678963C
(en)
|
2007-02-23 |
2018-05-01 |
Elan Pharmaceuticals, Inc. |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
US20120142902A1
(en)
|
2007-02-23 |
2012-06-07 |
The Regents Of The University Of California |
Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
|
WO2008106660A2
(en)
|
2007-03-01 |
2008-09-04 |
Invitrogen Corporation |
Isolated phospholipid-protein particles
|
US20100105134A1
(en)
|
2007-03-02 |
2010-04-29 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting gene expression and uses thereof
|
DE102007024382A1
(en)
|
2007-05-23 |
2008-11-27 |
Johann Wolfgang Goethe-Universität Frankfurt am Main |
Diagnosing a neurodegenerative disease comprises the gene expression level of a specified marker in a biological sample
|
DE102007036200A1
(en)
|
2007-08-02 |
2009-02-05 |
Knorr-Bremse Systeme für Nutzfahrzeuge GmbH |
Inductive displacement or rotation angle sensor with shielding plate arranged between two coils
|
PL2195017T3
(en)
|
2007-10-01 |
2015-03-31 |
Bristol Myers Squibb Co |
Human antibodies that bind mesothelin, and uses thereof
|
EP2210104A4
(en)
|
2007-11-01 |
2011-02-23 |
Univ Arizona State |
Cell-free methods for detecting protein-ligand interctions
|
WO2009059278A1
(en)
|
2007-11-02 |
2009-05-07 |
Centocor, Inc. |
Semi-synthetic glp-1 peptide-fc fusion constructs, methods and uses
|
US20110085970A1
(en)
|
2007-11-30 |
2011-04-14 |
Terrett Jonathan A |
Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
|
TW200938223A
(en)
|
2007-11-30 |
2009-09-16 |
Medarex Inc |
Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (PTK7)
|
US20090169549A1
(en)
|
2007-12-19 |
2009-07-02 |
The Board Of Regents Of The University Of Texas System |
Conformational isomers of alpha-synuclein, antibodies thereto and methods of their manufacture and use
|
GB0802851D0
(en)
|
2008-02-15 |
2008-03-26 |
Medinnova As |
Diagnostic method
|
US20100040635A1
(en)
*
|
2008-03-28 |
2010-02-18 |
Sea Lane Biotechnologies |
Neutralizing antibodies to influenza viruses
|
EP3470079A1
(en)
|
2008-04-29 |
2019-04-17 |
BioArctic AB |
Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders
|
CN101570575B
(en)
|
2008-04-30 |
2012-02-29 |
北京市肿瘤防治研究所 |
Sncg monoclonal antibody and application thereof
|
NZ588442A
(en)
|
2008-06-09 |
2013-01-25 |
Univ Muenchen L Maximilians |
Pyrazole, isoxazole and imidazole derivatives for treating diseases linked to protein aggregation and neurodegenerative diseases
|
WO2009152607A1
(en)
|
2008-06-16 |
2009-12-23 |
Ottawa Hospital Research Institute |
Methods and kits for diagnosing neurodegenerative disease
|
AR072999A1
(en)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
|
JP2012502967A
(en)
*
|
2008-09-19 |
2012-02-02 |
メディミューン,エルエルシー |
Antibodies against sonic hedgehog homologs and uses thereof
|
EP3521309A1
(en)
|
2008-12-19 |
2019-08-07 |
Biogen International Neuroscience GmbH |
Human anti-alpha-synuclein antibodies
|
US9203280B2
(en)
|
2009-07-16 |
2015-12-01 |
Ibaraki University |
Magnetic levitation control device and hybrid type magnetic bearing
|
US9125846B2
(en)
|
2010-10-15 |
2015-09-08 |
The Board Of Regents Of The University Of Texas System |
Antibodies that bind amyloid oligomers
|
CA2677068A1
(en)
|
2009-09-01 |
2011-03-01 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting gene expression and uses thereof
|
WO2011027308A1
(en)
|
2009-09-03 |
2011-03-10 |
Koninklijke Philips Electronics N.V. |
Novel tumor markers
|
US20120190652A1
(en)
|
2009-09-16 |
2012-07-26 |
United Arab Emirates University |
Diagnostic agent for parkinson's disease
|
CN101692092B
(en)
|
2009-09-24 |
2013-04-10 |
首都医科大学宣武医院 |
Method for quantitatively detecting alpha-synuclein auto-antibodies in human sera
|
DK2954779T3
(en)
|
2009-12-10 |
2019-05-13 |
Regeneron Pharma |
Mice that produce heavy chain antibodies
|
US20120021409A1
(en)
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
RU2724663C2
(en)
|
2010-02-08 |
2020-06-25 |
Ридженерон Фармасьютикалз, Инк. |
Mouse with common light chain
|
HUE038313T2
(en)
*
|
2010-02-26 |
2018-10-29 |
Bioarctic Neuroscience Ab |
Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
|
EP2366714A1
(en)
|
2010-03-03 |
2011-09-21 |
Dr. Rentschler Holding GmbH & Co. KG |
Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
|
US20130029998A1
(en)
|
2010-05-11 |
2013-01-31 |
Chandra Shekhar Mayanil |
Method of Detecting and Profiling Progression of the Risk of Neurodegenerative Diseases
|
RS55042B1
(en)
|
2010-06-22 |
2016-12-30 |
Regeneron Pharma |
Mice expressing an immunoglobulin hybrid light chain with a human variable region
|
WO2012032519A2
(en)
|
2010-09-07 |
2012-03-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Methods of diagnosing parkinson's disease
|
US20130309690A1
(en)
|
2010-11-05 |
2013-11-21 |
The Brigham And Women's Hospital, Inc. |
Tetrameric alpha-synuclein as biomarkers
|
WO2012061785A2
(en)
|
2010-11-05 |
2012-05-10 |
Brandeis University |
Ice inhibiting compounds and uses thereof
|
CA2818171A1
(en)
|
2010-11-24 |
2012-06-07 |
Elan Pharmaceuticals, Inc. |
Phagocytic activity as a marker of synucleinopathic disease
|
KR101308898B1
(en)
|
2011-02-08 |
2013-09-23 |
건국대학교 산학협력단 |
A NOVEL ANTI-α-CYNUCLEIN MONOCLONAL ANTIBADY AND ELISA SYSTEM USING THE SAME
|
KR20120093002A
(en)
|
2011-02-14 |
2012-08-22 |
(주)에이티젠 |
Method for diagnosing cancer and diagnosis kit using measurement of nk cell activity
|
WO2012170993A2
(en)
|
2011-06-09 |
2012-12-13 |
New York University |
Assays and methods pertaining to pre-amyloid intermediates
|
WO2012177639A2
(en)
|
2011-06-22 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Bioprocessing and bioproduction using avian cell lines
|
TR201815563T4
(en)
|
2011-06-23 |
2018-11-21 |
Biogen Int Neuroscience Gmbh |
Anti-alpha synuclein binding molecules.
|
WO2013012811A2
(en)
|
2011-07-19 |
2013-01-24 |
New York University |
Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
|
ES2711876T3
(en)
|
2011-09-19 |
2019-05-08 |
C2N Diagnostics |
Methods for the diagnosis and treatment of neurological and neurodegenerative diseases, disorders and associated processes
|
ES2937409T3
(en)
|
2011-10-28 |
2023-03-28 |
Prothena Biosciences Ltd |
Humanized antibodies that recognize alpha-synuclein
|
MX356797B
(en)
|
2011-11-02 |
2018-06-14 |
Biogen Int Neuroscience Gmbh |
USE OF AN ANTI-alpha-SYNUCLEIN ANTIBODY TO DIAGNOSE AN ELEVATED LEVEL OF alpha-SYNUCLEIN IN THE BRAIN.
|
EP2807188B1
(en)
*
|
2012-01-27 |
2019-09-11 |
Prothena Biosciences Limited |
Humanized antibodies that recognize alpha-synuclein
|
EP2833920A2
(en)
|
2012-04-02 |
2015-02-11 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of biologics and proteins associated with human disease
|
EP2659907A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659906A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
US20150139937A1
(en)
|
2012-05-18 |
2015-05-21 |
Board Of Regents Of The University Of Nebraska |
Methods and Compositions For Inhibiting Diseases of the Central Nervous System
|
GB201212528D0
(en)
|
2012-07-13 |
2012-08-29 |
Isis Innovation |
Assay
|
US20140018250A1
(en)
|
2012-07-13 |
2014-01-16 |
Alexander Abbas |
Compositions and methods for the treatment of immune related diseases
|
US20140056901A1
(en)
|
2012-08-21 |
2014-02-27 |
The Institute For Molecular Medicine |
Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
|
US11246800B2
(en)
|
2012-10-05 |
2022-02-15 |
Alixa Rx, Llc |
Locking canister for dispensing medications
|
UA118441C2
(en)
|
2012-10-08 |
2019-01-25 |
Протена Біосаєнсиз Лімітед |
Antibodies recognizing alpha-synuclein
|
EP3508215A3
(en)
|
2012-12-03 |
2019-10-02 |
Bristol-Myers Squibb Company |
Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
|
WO2014132249A1
(en)
|
2013-02-26 |
2014-09-04 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Method for the assay of synucleins
|
US9534044B2
(en)
|
2013-02-28 |
2017-01-03 |
United Arab Emirates University |
Alpha-synuclein antibodies and uses thereof
|
US20140241987A1
(en)
|
2013-02-28 |
2014-08-28 |
United Arab Emirates University |
Alpha-synuclein antibodies and uses thereof
|
AU2013203043B2
(en)
|
2013-03-15 |
2016-10-06 |
Takeda Pharmaceutical Company Limited |
Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
|
EP2787348A1
(en)
|
2013-04-03 |
2014-10-08 |
Affiris AG |
Method for detecting aSyn-specific antibodies in a biological sample
|
DE102013106713A1
(en)
|
2013-06-26 |
2014-12-31 |
Forschungszentrum Jülich GmbH |
Method for identifying indicators for the determination of diseases
|
US10513555B2
(en)
|
2013-07-04 |
2019-12-24 |
Prothena Biosciences Limited |
Antibody formulations and methods
|
CN106163540A
(en)
|
2013-09-13 |
2016-11-23 |
安达卢西亚进步与健康公共基金会 |
For treating albumen disease or the collectin of conformational disease and the combination of molecular chaperones
|
WO2015075635A2
(en)
|
2013-11-19 |
2015-05-28 |
Prothena Biosciences Limited |
Monitoring immunotherapy of lewy body disease from constipation symptoms
|
EP3071597B1
(en)
|
2013-11-21 |
2020-07-29 |
F.Hoffmann-La Roche Ag |
Anti-alpha-synuclein antibodies and methods of use
|
PL3083680T3
(en)
|
2013-12-20 |
2020-06-29 |
F. Hoffmann-La Roche Ag |
Humanized anti-tau(ps422) antibodies and methods of use
|
US11073470B2
(en)
|
2014-02-14 |
2021-07-27 |
Betasense Gmbh |
Attenuated total reflectance-based biosensor for conformation and secondary structure analysis
|
US9618524B2
(en)
|
2014-03-26 |
2017-04-11 |
Plaxgen Inc. |
Method, composition, isolation and identification of a plaque particle and related biomarker
|
EP3129051A1
(en)
|
2014-04-08 |
2017-02-15 |
Prothena Biosciences Limited |
Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
|
WO2015157117A2
(en)
|
2014-04-09 |
2015-10-15 |
The Trustees Of Columbia University In The City Of New York |
Use of leukocytes and novel biomarkers in the diagnosis, confirmation, and treatment of a neurological disorder
|
WO2015179867A1
(en)
|
2014-05-23 |
2015-11-26 |
University Of South Florida |
Methods, antibodies, and vaccines utilizing epitopes of alpha synuclein for treatment of parkinson's disease
|
AU2015314783B2
(en)
|
2014-09-11 |
2021-10-21 |
Amprion, Inc. |
Detection of misfolded proteins
|
CN104215777B
(en)
|
2014-09-18 |
2016-01-20 |
首都医科大学宣武医院 |
A kind ofly detect the method for haemoglobin in conjunction with phosphorylation alpha-synapse nucleoprotein
|
CN104215779B
(en)
|
2014-09-18 |
2016-01-20 |
首都医科大学宣武医院 |
A kind ofly detect the method for haemoglobin in conjunction with alpha-synapse nucleoprotein
|
US9732148B2
(en)
|
2014-10-16 |
2017-08-15 |
Genentech, Inc. |
Anti-α-synuclein antibodies and methods of use
|
KR101658620B1
(en)
|
2014-12-02 |
2016-09-23 |
주식회사 피플바이오 |
Method for Detecting Aggregate Form of Aggregate-Forming Polypeptides
|
AU2016218977C1
(en)
|
2015-02-13 |
2023-03-23 |
Factor Bioscience Inc. |
Nucleic acid products and methods of administration thereof
|
GB201512203D0
(en)
|
2015-07-13 |
2015-08-19 |
Lundbeck & Co As H |
Agents,uses and methods
|
GB2541003A
(en)
|
2015-08-05 |
2017-02-08 |
Kran Life Sciences Llp |
Neurodegenerative disorders
|
US10852309B2
(en)
|
2015-08-25 |
2020-12-01 |
Prothena Biosciences Limited |
Methods for detecting phosphorylated alpha-synuclein
|
GB201515223D0
(en)
|
2015-08-27 |
2015-10-14 |
Georg August Uni Gottingen Stiftung Offentlichen Rechts Universitatsmedizin |
Method of differential diagnosis of dementia with Lewy bodies and Parkinson's disease
|
JP2019501115A
(en)
|
2015-10-28 |
2019-01-17 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Intrathecal administration of adeno-associated virus vector for gene therapy
|
EP3181701A1
(en)
|
2015-12-17 |
2017-06-21 |
Consejo Superior De Investigaciones Cientificas |
Method for the sub-classification of patients suffering from parkinson disease
|
WO2017147529A1
(en)
|
2016-02-24 |
2017-08-31 |
The Trustees Of Columbia University In The City Of New York |
Disruption of the interaction between amyloid beta peptide and dietary lipids
|
EP3430397B1
(en)
|
2016-03-14 |
2022-02-23 |
Biogen International Neuroscience GmbH |
Antibody-dependent cell-mediated phagocytosis assay for reliably measuring uptake of aggregated proteins
|
US10766954B2
(en)
|
2016-04-06 |
2020-09-08 |
Imago Pharmaceuticals, Inc. |
Therapeutic antibodies for treatment of neurodegeneration
|
US11446398B2
(en)
|
2016-04-11 |
2022-09-20 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
ES2650175B1
(en)
|
2016-04-15 |
2019-02-04 |
Servicio Andaluz De Salud |
Treatment of neurodegenerative diseases
|
US20190137490A1
(en)
|
2016-05-06 |
2019-05-09 |
Duke University |
Methods and kits for diagnosing and treating nervous system disease or injury
|
KR102499438B1
(en)
|
2016-06-02 |
2023-02-14 |
메디뮨 리미티드 |
Antibodies to alpha-synuclein and uses thereof
|
EP3478316A1
(en)
|
2016-07-01 |
2019-05-08 |
Declion Holdings LLC |
Amino acid copolymer compositions and uses thereof
|
EP3482210B1
(en)
|
2016-07-06 |
2021-06-23 |
Prothena Biosciences Limited |
Assay for detecting total and s129 phosphorylated alpha-synuclein
|
AU2017297804A1
(en)
|
2016-07-14 |
2019-01-24 |
Bioarctic Ab |
Brain delivery protein
|
WO2018022479A1
(en)
|
2016-07-25 |
2018-02-01 |
Biogen Ma Inc. |
Anti-hspa5 (grp78) antibodies and uses thereof
|
US20190170771A1
(en)
|
2016-07-28 |
2019-06-06 |
Lysosomal And Rare Disorders Research And Treatment Center, Llc. |
Alpha-synuclein in peripheral blood mononuclear cells as biomarker for synucleinopathy
|
WO2018039147A1
(en)
|
2016-08-23 |
2018-03-01 |
The Johns Hopkins University |
THERAPEUTIC USES OF LAG3 THE α-SYNUCLEIN TRANSMISSION RECEPTOR
|
US20180128840A1
(en)
|
2016-11-08 |
2018-05-10 |
Magqu Co. Ltd. |
Method for identifying parkinson disease dementia from parkinson disease
|
US20180126191A1
(en)
|
2016-11-09 |
2018-05-10 |
The Trustees Of Columbia University In The City Of New York |
Methods for reducing inflammation with surface acoustic waves
|
KR102593669B1
(en)
|
2016-11-15 |
2023-10-25 |
하. 룬드벡 아크티에셀스카브 |
Agents, uses and methods for the treatment of synucleinopathies
|
US20180134775A1
(en)
|
2016-11-17 |
2018-05-17 |
United Arab Emirates University |
Alpha-Synuclein Antibodies (7A11)
|
US20180134777A1
(en)
|
2016-11-17 |
2018-05-17 |
United Arab Emirates University |
Alpha-Synuclein Antibodies (11D12)
|
US20180134776A1
(en)
|
2016-11-17 |
2018-05-17 |
United Arab Emirates University |
Alpha-Synuclein Antibodies (4H6)
|
WO2018102763A1
(en)
|
2016-12-02 |
2018-06-07 |
Prothena Biosciences Limited |
Infrared assay detecting secondary structure profiles of alpha-synuclein
|
JP6273338B1
(en)
|
2016-12-05 |
2018-01-31 |
磁量生技股▲ふん▼有限公司 |
How to identify Parkinson's disease dementia from Parkinson's disease
|
JP2020511963A
(en)
|
2016-12-12 |
2020-04-23 |
ザ マイケル ジェイ. フォックス ファウンデーション フォー パーキンソンズ リサーチ |
Antibodies to human alpha-synuclein
|
MA47019A
(en)
|
2016-12-16 |
2021-04-21 |
H Lundbeck As |
AGENTS, USES AND METHODS
|
US10364286B2
(en)
|
2016-12-22 |
2019-07-30 |
H. Lundbeck A/S |
Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
|
WO2018128454A1
(en)
|
2017-01-06 |
2018-07-12 |
에이비엘바이오 주식회사 |
ANTI-α-SYN ANTIBODY AND USE THEREOF
|
SG11201906947SA
(en)
|
2017-02-17 |
2019-08-27 |
Bristol Myers Squibb Co |
Antibodies to alpha-synuclein and uses thereof
|
JOP20190227A1
(en)
|
2017-03-31 |
2019-09-30 |
Biogen Int Neuroscience Gmbh |
Compositions and methods for treating synucleinopathies
|
WO2018204352A1
(en)
|
2017-05-01 |
2018-11-08 |
The Trustees Of The University Of Pennsylvania |
Monoclonal antibodies against alpha-synuclein fibrils
|
WO2018204764A1
(en)
|
2017-05-05 |
2018-11-08 |
Camp4 Therapeutics Corporation |
Identification and targeted modulation of gene signaling networks
|
US20180344869A1
(en)
|
2017-05-18 |
2018-12-06 |
Hoffmann-La Roche Inc. |
Reduction of application-related side reaction of a therapeutic antibody
|
EP3406632A1
(en)
|
2017-05-23 |
2018-11-28 |
S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati |
Ligands binding to prion protein for use in the treatment of synucleinopathies
|
EP3631446B1
(en)
|
2017-05-29 |
2024-04-17 |
betaSENSE GmbH |
Biosensor for conformation and secondary structure analysis
|
WO2018226590A1
(en)
|
2017-06-05 |
2018-12-13 |
The Trustees Of Columbia University In The City Of New York |
Peptides as biomarkers in the diagnosis, confirmation and treatment of a neurological disorder and immunoprofiling in neurodegenerative disease
|
WO2018232176A1
(en)
|
2017-06-16 |
2018-12-20 |
The University Of Chicago |
Compositions and methods for inducing immune tolerance
|
JP2021508672A
(en)
|
2017-06-16 |
2021-03-11 |
ユナイテッド ニューロサイエンスUnited Neuroscience |
Peptide immunogenicity from the C-terminus of alpha-synuclein protein for the treatment of synucleinopathy and its preparations
|
WO2018236986A1
(en)
|
2017-06-20 |
2018-12-27 |
The Trustees Of Columbia University In The City Of New York |
Engineered t-cell receptors and methods of their use
|
WO2018237338A1
(en)
|
2017-06-23 |
2018-12-27 |
Denali Therapeutics Inc. |
Anti-alpha-synuclein antibodies and methods of use thereof
|
WO2019023809A1
(en)
|
2017-08-02 |
2019-02-07 |
Stressmarq Biosciences Inc. |
Antibody binding active alpha-synuclein
|
WO2019040617A1
(en)
|
2017-08-23 |
2019-02-28 |
The Trustees Of The University Of Pennsylvania |
Monoclonal antibodies against pathological alpha-synuclein, and methods using same
|
CN109490542A
(en)
|
2017-09-11 |
2019-03-19 |
博尔诚(北京)科技有限公司 |
Colloidal gold detection device of γ synapse nucleoprotein and its preparation method and application
|
JP2021502955A
(en)
|
2017-09-28 |
2021-02-04 |
プロセナ・バイオサイエンシズ・リミテッド |
Administration regimen for the treatment of synuclein disease
|
US20190153102A1
(en)
|
2017-09-28 |
2019-05-23 |
Prothena Biosciences Limited |
Dosing regimes for treatment of synucleinopathies
|
WO2019094679A1
(en)
|
2017-11-10 |
2019-05-16 |
The Regents Of The University Of California |
BRAIN DELIVERY OF THE BACE INHIBITOR SAPPALPHA, ANTIBODIES, OR INHIBITORY RNA's USING SYNTHETIC EXOSOMES (DEFORMABLE NANOVESICLES, DNVs)
|
JP7173618B2
(en)
|
2017-11-17 |
2022-11-16 |
エービーエル バイオ インコーポレイテッド |
Antibodies against alpha-synuclein and uses thereof
|
AU2018385230B2
(en)
|
2017-12-14 |
2022-10-13 |
Abl Bio Inc. |
Bispecific antibody to a-syn/IGF1R and use thereof
|
GB201720970D0
(en)
|
2017-12-15 |
2018-01-31 |
Ucb Biopharma Sprl |
Antibodies
|
GB201720975D0
(en)
|
2017-12-15 |
2018-01-31 |
Ucb Biopharma Sprl |
Anti-alpha synuclein antibodies
|
GB201720978D0
(en)
|
2017-12-15 |
2018-01-31 |
Ucb Biopharma Sprl |
Anti-alpha synuclein antibodies
|
EP3729088B1
(en)
|
2017-12-21 |
2021-10-20 |
H. Lundbeck A/S |
Diagnosis and treatment of alpha-synucleinopathies
|
BR112020012921A2
(en)
|
2018-01-12 |
2020-12-08 |
Roche Innovation Center Copenhagen A/S |
ALPHA-SINUCLEIN ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF
|
SG11202006528XA
(en)
|
2018-01-12 |
2020-08-28 |
Bristol Myers Squibb Co |
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
|
WO2019157527A2
(en)
|
2018-02-12 |
2019-08-15 |
The Scripps Research Institute |
Methods related to parkinson's disease and synucleinopathies
|
WO2019161386A1
(en)
|
2018-02-19 |
2019-08-22 |
New York University |
Alpha-synuclein single domain antibodies
|
WO2019169496A1
(en)
|
2018-03-08 |
2019-09-12 |
Purepharm Inc. |
Methods and compositions for preventing and treating conditions related to alpha-synuclein
|
WO2019169448A1
(en)
|
2018-03-09 |
2019-09-12 |
St Vincent's Institute Of Medical Research |
Multi-specific antibodies
|
WO2019175883A1
(en)
|
2018-03-14 |
2019-09-19 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd |
Detection of phospho-serine 129 alpha-synuclein in blood cells as a biomarker for synucleinopathies
|
JP2021522812A
(en)
|
2018-05-07 |
2021-09-02 |
アノキオン・ソシエテ・アノニムAnokion Sa |
Glycophorin A antigen-binding protein
|
EA202092723A1
(en)
|
2018-05-09 |
2021-04-09 |
Зе Юниверсити Оф Чикаго |
COMPOSITIONS AND METHODS CONCERNING IMMUNE TOLERANCE
|
CN112533959A
(en)
|
2018-05-22 |
2021-03-19 |
阿尔伯塔大学理事会 |
Harmless, structured scaffolds for structure-based amyloid disease vaccines and antigens
|
WO2019224275A1
(en)
|
2018-05-23 |
2019-11-28 |
Adc Therapeutics Sa |
Molecular adjuvant
|
WO2020003203A1
(en)
|
2018-06-27 |
2020-01-02 |
Mor Research Applications |
Antibodies for the treatment of synucleinopathies and neuroinflammation
|
WO2020009482A1
(en)
|
2018-07-03 |
2020-01-09 |
에이비엘바이오 주식회사 |
Anti-alpha-synuclein antibody and use thereof
|
CN109001452A
(en)
|
2018-07-26 |
2018-12-14 |
上海纳米技术及应用国家工程研究中心有限公司 |
Preparation method of detection probe of alpha-synapse nucleoprotein accumulation and products thereof and application
|
AU2019318195A1
(en)
|
2018-08-09 |
2021-03-04 |
F. Hoffmann-La Roche Ag |
Determination of parkinson's disease
|
JP7173532B2
(en)
|
2018-08-28 |
2022-11-16 |
学校法人順天堂 |
Diagnosis of α-Synucleinopathy
|
US20230051538A1
(en)
|
2018-10-07 |
2023-02-16 |
The University Of British Columbia |
Conformation-specific epitopes in alpha-synuclein, antibodies thereto and methods related thereof
|
EP3867270A1
(en)
|
2018-10-19 |
2021-08-25 |
Janssen Vaccines & Prevention B.V. |
Anti-synuclein antibodies
|
CN109268774A
(en)
|
2018-10-25 |
2019-01-25 |
华域视觉科技(上海)有限公司 |
A kind of double matrix form illumination module and its auxiliary lighting method
|
US20200132683A1
(en)
|
2018-10-25 |
2020-04-30 |
Integrated Neurologics LLC |
Rapid multiplex diagnostic for parkinson's disease and alzheimer's disease
|
AR114808A1
(en)
|
2018-12-14 |
2020-10-21 |
Ucb Biopharma Sprl |
ANTI-a-SINUCLEIN ANTIBODIES
|
TWI734279B
(en)
|
2018-12-14 |
2021-07-21 |
美商美國禮來大藥廠 |
Anti-alpha-synuclein antibodies and uses thereof
|
WO2020146497A1
(en)
|
2019-01-09 |
2020-07-16 |
The Regents Of The University Of California |
An electrochemiluminescence elisa for ps129-a-synuclein
|
US11542322B2
(en)
|
2019-02-13 |
2023-01-03 |
Iowa State University Research Foundation, Inc. |
Nano-theranostics for Parkinson's disease
|
EP3935159A1
(en)
|
2019-03-08 |
2022-01-12 |
Obsidian Therapeutics, Inc. |
Human carbonic anhydrase 2 compositions and methods for tunable regulation
|
EP3941452A1
(en)
|
2019-03-18 |
2022-01-26 |
The Regents of the University of California |
Small molecules targeting the intrinsically disordered structural ensemble of alpha-synuclein protect against diverse alpha-synuclein mediated dysfunctions
|
KR20210150486A
(en)
|
2019-04-10 |
2021-12-10 |
프리베일 테라퓨틱스, 인크. |
Gene therapy for lysosomal disorders
|
JP2022529344A
(en)
|
2019-04-18 |
2022-06-21 |
エイシー イミューン ソシエテ アノニム |
New molecules for treatment and diagnosis
|
EP3959323A1
(en)
|
2019-04-24 |
2022-03-02 |
REGENXBIO Inc. |
Fully-human post-translationally modified antibody therapeutics
|
CN110172098B
(en)
|
2019-05-27 |
2023-03-10 |
长春工业大学 |
Monoclonal antibody for resisting alpha-synuclein and application thereof
|
PE20231029A1
(en)
|
2019-06-14 |
2023-07-10 |
Abl Bio Inc |
BISECIFIC ANTIBODY AGAINST (alpha)-SYN/IGF1R AND USE THEREOF
|
US20220378801A1
(en)
|
2019-06-21 |
2022-12-01 |
Ac Immune Sa |
Novel compounds
|
EP3779448A1
(en)
|
2019-08-12 |
2021-02-17 |
Baden-Württemberg Stiftung gGmbH |
Novel diagnostic marker for creutzfeldt-jakob disease and alzheimer's disease
|